Lantus (Insulin Glargine) in Girls Under 12: What Families and Young Patients Need to Know About Transitioning to Adult Care

What Is Lantus and Why Is It Used in Young Girls?

Lantus (insulin glargine) is a basal insulin analog that provides a steady, peakless background insulin level over approximately 24 hours. For a girl with type 1 diabetes, the pancreas produces little to no insulin, and Lantus fills that baseline gap. It is one of the most prescribed long-acting insulins in the pediatric setting because of its predictable action profile compared to older NPH insulin.

The FDA approved Lantus for use in children aged 6 and older with type 1 diabetes mellitus. In clinical practice, some endocrinologists use it off-label in children younger than 6, including girls under age 12 as referenced in this article, when the clinical picture calls for it.

How Lantus Works Differently in Young Bodies

Insulin glargine is injected subcutaneously once daily, most often at bedtime or at the same time each morning. After injection, it forms microprecipitates under the skin that dissolve slowly, releasing insulin in a consistent, low-level stream. This is distinct from rapid-acting insulins like lispro or aspart, which a child also takes at mealtimes.

Children generally have higher insulin sensitivity than adults, which means smaller doses per kilogram can have significant effects. A typical starting dose in pediatric type 1 diabetes is 0.2 to 0.4 units per kg per day for basal insulin, though total daily dose needs are highly individual and adjusted frequently in growing children.

Why This Matters More for Girls Than Boys

Girls face a sex-specific set of metabolic challenges with diabetes that start before puberty and compound across their reproductive lives. Estrogen and progesterone directly affect insulin receptor sensitivity. Even before menstruation begins, the hormonal shifts of early puberty, which typically start between ages 8 and 13 in girls, begin to change how much Lantus a girl needs.

Insulin Needs Across Early Life Stages in Girls

Before Puberty (Ages Under 8)

Very young girls with type 1 diabetes are often in a honeymoon phase immediately after diagnosis, during which residual beta-cell function means lower insulin requirements. Basal insulin needs are modest. The goal is tight enough control to avoid hyperglycemic damage while avoiding hypoglycemia, which in young children can impair neurodevelopment.

The American Diabetes Association's Standards of Care recommend an HbA1c target of below 7.0 percent for most children, though individualized targets apply when hypoglycemia is a significant concern.

Early Puberty (Ages 8 to 12)

This is where insulin requirements in girls begin to diverge from boys and from their own pre-pubertal baseline. The adrenal glands begin producing androgens (adrenarche), and the pituitary releases more growth hormone. Growth hormone is a counter-regulatory hormone. It opposes insulin action, raising blood glucose and signaling the pancreas, or in this case the injection regimen, to compensate.

Insulin requirements during puberty can increase by 30 to 50 percent compared to pre-pubertal doses. A girl who was stable on 10 units of Lantus at age 9 may need 14 to 15 units by age 11, sometimes more.

Frequent dose adjustments are expected during this period. Families should not interpret rising Lantus doses as treatment failure.

What to Watch for in Girls Specifically at This Stage

Girls aged 8 to 12 with type 1 diabetes are at elevated risk for several female-specific concerns:

• Disordered eating and insulin omission. Research published in Diabetes Care found that girls with type 1 diabetes are 2.4 times more likely to develop an eating disorder than girls without diabetes. Deliberate insulin restriction to lose weight, called diabulimia, is particularly dangerous and difficult to detect.
• Early menstrual irregularity. Poorly controlled diabetes can delay the onset of menstruation or cause irregular cycles. The hypothalamic-pituitary-ovarian axis is sensitive to metabolic disruption.
• PCOS risk. Girls with type 1 diabetes who develop insulin resistance have a higher prevalence of polycystic ovary syndrome than the general population, which compounds the difficulty of achieving glycemic targets.

Managing the Pediatric-to-Adult Care Transition

The move from a pediatric endocrinology team to an adult diabetes care practice is one of the highest-risk periods in the clinical life of a young woman with type 1 diabetes. Studies consistently show that HbA1c worsens during this window, and rates of diabetes-related hospitalizations spike.

A structured transition framework for girls with type 1 diabetes, based on current pediatric endocrinology guidance and sex-specific risk data, looks like this:

Phase 1: Preparation (Ages 10 to 14)

Start building self-management skills early. The girl, not only her parent, should begin attending parts of clinic appointments alone. She should be able to:

• State her Lantus dose and timing independently
• Recognize and treat a hypoglycemic episode without adult prompting
• Understand that her insulin needs will change with her menstrual cycle once periods begin
• Know what to do if she is sick (sick-day rules)

Continuous glucose monitoring (CGM) should be in place before the transition if at all possible. CGM use in adolescents with type 1 diabetes is associated with a 0.4 percent reduction in HbA1c in the DIAMOND trial, with benefits extending into young adulthood when CGM is maintained.

Phase 2: Active Transfer (Ages 17 to 21)

The transition should not be a single appointment. Best practice is a minimum of 6 months of overlap, where the pediatric and adult teams communicate directly. The American Diabetes Association and ISPAD recommend a written transition plan that travels with the patient.

Key items for the young woman's written transition document:

• Current Lantus dose, injection site rotation pattern, and any recent dose changes
• HbA1c trajectory over the past 2 years
• History of severe hypoglycemia or diabetic ketoacidosis
• Menstrual cycle regularity and any noted pattern of glycemic changes around her period
• Contraception status and plans, because pregnancy requires a different insulin strategy
• Mental health and disordered eating screening results
• Thyroid function tests (girls with type 1 diabetes have higher rates of autoimmune thyroiditis)

Phase 3: Settling Into Adult Care (Ages 21 to 25)

Adult endocrinologists approach diabetes management differently than pediatric teams. The paternalistic scaffolding decreases and the young woman bears more responsibility. This phase has the highest dropout rate from care.

Female-specific conversations that must happen in adult care and are often missed:

• How her menstrual cycle affects her Lantus dose (covered in the next section)
• Preconception counseling, because type 1 diabetes is a high-risk pregnancy condition
• The relationship between insulin therapy and body weight, and how to manage weight changes without compromising glycemic control
• Contraception choices that are compatible with diabetes (estrogen-containing contraceptives can worsen insulin resistance in some women)

How the Menstrual Cycle Changes Lantus Dosing

Once a girl begins menstruating, her insulin needs follow a predictable hormonal rhythm. This is one of the most under-discussed aspects of type 1 diabetes management in young women, and one of the places where women-centered care makes the biggest practical difference.

Follicular Phase (Days 1 to 14)

Estrogen rises during the follicular phase. Estrogen generally improves insulin sensitivity, meaning blood glucose tends to run lower and Lantus requirements may be slightly reduced. Many women notice fewer hypoglycemic episodes in the first half of their cycle.

Luteal Phase (Days 15 to 28)

After ovulation, progesterone rises sharply. Progesterone is insulin-antagonistic. Research in Diabetic Medicine found that insulin requirements increase by an average of 10 to 26 percent in the luteal phase of the menstrual cycle in women with type 1 diabetes. Blood glucose runs higher, and the Lantus dose that worked perfectly in week 2 of the cycle may be insufficient in week 3.

Practical guidance: keep a 2-month cycle diary tracking glucose patterns alongside cycle day. This gives your diabetes care team the data needed to recommend a small luteal-phase Lantus dose adjustment, rather than repeatedly troubleshooting what looks like unexplained hyperglycemia.

Perimenstrual Period (Days 26 to 2)

The drop in progesterone just before menstruation can cause a sharp drop in blood glucose. Some women experience significant hypoglycemia in the 24 to 48 hours before their period starts, followed by glucose stabilization once menstruation begins.

Pregnancy, Lactation, and Contraception: What You Must Know Before Trying to Conceive

This section is required reading for any woman with type 1 diabetes who is in her reproductive years.

Pregnancy Safety of Lantus

Lantus carries an FDA Pregnancy Category C designation, meaning animal reproduction studies have shown adverse effects and there are no adequate, well-controlled studies in pregnant women. Human data on insulin glargine in pregnancy are limited, though a growing number of observational studies have tracked outcomes.

The GLAT study and several registry analyses suggest that insulin glargine does not appear to increase congenital malformation rates compared to NPH insulin. However, most major obstetric guidelines, including ACOG's guidance on pregestational diabetes, still recommend switching to NPH or insulin detemir during pregnancy if glycemic control allows, because the safety data on glargine remain less complete than for older formulations.

Insulin detemir (Levemir) has somewhat more pregnancy-specific data and is often the preferred long-acting insulin in pregnancy. Your obstetric endocrinologist will guide this choice.

Glycemic Control Before Conception Is Non-Negotiable

Women with type 1 diabetes who conceive with an HbA1c above 10 percent face a congenital malformation risk of approximately 20 to 25 percent. The goal before conception is an HbA1c below 6.5 percent if achievable without significant hypoglycemia. This requires active, structured preconception care, not a reactive approach once pregnancy is confirmed.

Lactation

Insulin glargine is a large protein molecule. Very little crosses into breast milk, and what does transfer is unlikely to be absorbed intact by the infant's gastrointestinal tract. Current guidance considers insulin therapy compatible with breastfeeding. Insulin requirements drop substantially after delivery and during lactation because breastfeeding itself improves insulin sensitivity. Close monitoring and dose reduction are needed postpartum to avoid hypoglycemia.

Contraception for Women on Lantus

Lantus itself does not interact with contraceptives. However, the underlying condition, type 1 diabetes, does interact with some contraceptive methods:

• Combined oral contraceptives (COCs): Estrogen and progestin in COCs can worsen insulin resistance. For most women with well-controlled type 1 diabetes and no vascular complications, low-dose COCs are acceptable. For those with hypertension, nephropathy, or retinopathy, progestin-only or non-hormonal methods are preferred.
• Progestin-only methods (mini-pill, hormonal IUD, implant): Generally safe in type 1 diabetes. Progestin-only methods cause less metabolic disruption than combined methods for most women.
• Non-hormonal methods (copper IUD): An excellent choice for women who want to avoid any hormonal effect on insulin sensitivity.

Contraception planning is especially important for young women on insulin because pregnancy in uncontrolled diabetes carries serious fetal risk. Use the most effective method you will actually use consistently.

PCOS, Thyroid Disease, and Other Female Conditions That Intersect With Insulin Glargine Use

PCOS

Girls with type 1 diabetes who develop insulin resistance in adolescence have a higher prevalence of PCOS. PCOS itself is characterized by insulin resistance independent of diabetes status. When the two conditions co-exist, glycemic management is harder, Lantus doses may be higher, and the hormonal chaos of irregular cycles further complicates glucose patterns.

Metformin is sometimes added in girls with type 1 diabetes and concurrent insulin resistance, though the evidence base for this is still developing. A 2019 Cochrane review found that metformin added to insulin in type 1 diabetes reduced insulin dose requirements but did not significantly improve HbA1c.

Autoimmune Thyroid Disease

Girls with type 1 diabetes have approximately 4 times the risk of autoimmune thyroid disease compared to the general population. Hypothyroidism slows metabolism and can cause hypoglycemia by reducing the clearance of insulin. Hyperthyroidism does the opposite. Annual thyroid function screening is standard of care in girls with type 1 diabetes. Any significant change in thyroid status will require Lantus dose re-evaluation.

Female Pattern Hair Loss and Hormonal Acne

Poorly controlled type 1 diabetes and the associated androgen excess sometimes seen with PCOS overlap can contribute to hormonal acne and, less commonly, hair changes. These are not direct effects of Lantus but are worth flagging to your care team as signs that glycemic and hormonal control need attention.

Bone Health: A Conversation That Starts in Childhood

Women with type 1 diabetes have lower bone mineral density than women without diabetes. A meta-analysis in Osteoporosis International found that type 1 diabetes is associated with a 6.9-fold increased risk of hip fracture. Bone accrual happens predominantly in the first two decades of life, which means the years when a girl is managing her diabetes on Lantus are also the years when her skeleton is being built.

Adequate vitamin D, calcium, and weight-bearing exercise during childhood and adolescence are non-negotiable. HbA1c above 8 percent in adolescence is independently associated with lower bone density. This is one more reason to optimize Lantus dosing and reach glycemic targets during the growing years.

Practical Dosing Notes for Girls and Young Women on Lantus

Injection Technique

Lantus is injected subcutaneously. Rotating injection sites prevents lipohypertrophy, which is a lumpy buildup of fat that alters insulin absorption and can cause unpredictable glucose levels. Common sites are the abdomen, outer thigh, and upper outer arm. Girls should rotate within each site systematically.

Timing

Most pediatric endocrinologists recommend a consistent once-daily injection time. Bedtime dosing is common in children to cover overnight basal needs, but if nocturnal hypoglycemia is a problem, morning dosing is an alternative.

Storage

Unopened Lantus vials and pens should be refrigerated at 36 to 46 degrees Fahrenheit. An in-use pen can be kept at room temperature (below 77 degrees Fahrenheit) for up to 28 days. Do not freeze.

What Happens if a Dose Is Missed

If a Lantus dose is missed, take it as soon as remembered the same day, then return to the usual dosing schedule the following day. Do not double a dose. Monitor glucose more frequently after a missed dose and watch for ketones if hyperglycemia develops.

"The transition from pediatric to adult diabetes care is not a handoff, it is a process," says Dr. Maya Okafor, MD, WomanRx editorial board member and women's health clinician. "For girls specifically, that process has to include an honest conversation about how hormones, periods, and eventual pregnancy planning will change every aspect of her insulin regimen. If we skip that conversation at age 17, we are setting her up for a crisis at age 22."

Evidence Gaps: What We Do Not Know Yet for Girls and Young Women

Women, and especially girls, have been systematically underrepresented in insulin pharmacokinetic trials. Most pharmacokinetic data on insulin glargine come from studies conducted predominantly in adult men or in mixed populations where sex-disaggregated analysis was not done.

Specific areas where the data in girls and women remain thin:

• How subcutaneous insulin absorption differs by body fat distribution across puberty in girls, compared to boys
• The precise magnitude of luteal-phase insulin requirement increase and whether a standardized dose adjustment protocol outperforms individualized titration
• Long-term outcomes of Lantus versus detemir in girls who later become pregnant
• Whether earlier structured transition programs reduce HbA1c deterioration specifically in young women versus young men

Where data is extrapolated from adult male studies to girls or young women, your clinical team is making an informed estimate, not applying a directly studied protocol. Ask your endocrinologist or NP what the evidence base is for any dose recommendation specific to your situation.